论文部分内容阅读
目的探讨肾移植术后患者应用他克莫司(FK506)的血药浓度与糖化血红蛋白(HbA1c)的相关关系。方法选取肾移植术后6个月以上应用他克莫司治疗的患者27例,测定患者应用他克莫司的血药浓度和在该血药浓度下患者的HbA1c的百分比,分析二者的相关关系。结果他克莫司的血药浓度与该血药浓度下患者的HbA1c的百分比具有相关性且为正相关,其相关系数为r=0.733,P<0.01(N=27);二者直线回归F=29.051,P<0.01(N=27)。结论肾移植患者术后应用他克莫司应对其进行血药浓度监测,同时还应对患者定期进行糖化血红蛋白的检测,尽可能减少由于应用他克莫司引起患者血糖升高给机体带来损伤。
Objective To investigate the relationship between plasma concentration of hemoglobin (HbA1c) and the concentration of FK506 in renal transplant recipients. Methods Twenty-seven patients received tacrolimus 6 months after renal transplantation were enrolled in this study. The plasma concentration of tacrolimus and the percentage of HbA1c in patients receiving tacrolimus were determined. The correlation between them was analyzed relationship. Results There was a positive correlation between the plasma concentration of tacrolimus and the percentage of HbA1c at the plasma concentration. The correlation coefficient was r = 0.733, P <0.01 (N = 27). The linear regression of F = 29.051, P <0.01 (N = 27). Conclusion The application of tacrolimus in renal transplant recipients should be monitored for plasma concentrations of HbA1c, while glycosylated hemoglobin should be tested regularly in patients with renal allograft to minimize the damage caused by elevated blood glucose in patients receiving tacrolimus.